全球癌症免疫療法藥物研發外包市場規模、佔有率、趨勢及成長分析報告（2026-2034年）

癌症免疫療法藥物研發外包市場規模預計將從 2025 年的 23 億美元成長到 2034 年的 56.2 億美元，2026 年至 2034 年的複合年成長率為 10.42%。

由於對創新癌症治療方法的需求不斷成長，以及藥物研發過程日益複雜，癌症免疫療法藥物研發外包市場預計將顯著成長。免疫療法是一種極具前景的治療方法，它利用人體自身的免疫系統來靶向並摧毀癌細胞。隨著製藥公司尋求加快藥物研發進程並降低成本，免疫療法研發活動的外包變得越來越普遍，預計該市場將穩步擴張。

此外，免疫療法技術的進步正在推動市場創新。單株抗體、CAR-T細胞療法和免疫查核點抑制劑等新型療法的研發正在革新癌症治療，並為外包合作創造了新的機會。這些創新不僅提高了癌症治療的療效，也需要專業的洞察力和資源，因此外包對許多機構來說都極具吸引力。隨著研發工作不斷探索新的免疫療法和聯合治療，在改善患者預後和加速藥物研發進程的推動下，免疫腫瘤藥物研發外包市場預計將進一步擴張。

此外，免疫腫瘤藥物研發外包領域正在經歷一場變革，合作與策略夥伴關係的重要性日益凸顯。隨著相關人員認知到利用外部專業知識和資源的價值，製藥公司與受託研究機構（CRO）之間的聯盟也變得越來越普遍。這些夥伴關係使企業能夠獲得專業知識、先進技術和高效流程，從而增強其藥物研發管線。隨著免疫腫瘤藥物研發外包市場的不斷發展，對合作與創新的重視將在推動未來成長方面發揮關鍵作用。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 繪製滲透率和成長前景圖
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場問題
• 波特五力分析
• PESTLE分析

第4章 全球癌症免疫療法藥物研發外包市場（依服務類型分類）

• 市場分析、洞察與預測
• 標靶分子鑑定與檢驗
• 先導篩檢與表徵
• 基於細胞的檢測

第5章 全球癌症免疫療法藥物研發外包市場（依癌症類型分類）

• 市場分析、洞察與預測
• 肺
• 乳癌
• 冒號
• 黑色素瘤
• 攝護腺
• 頭部和頸部
• 卵巢
• 胰臟

6. 全球癌症免疫療法藥物研發外包市場（依藥物類型分類）

• 市場分析、洞察與預測
• 單株抗體
• 免疫調節劑
• 癌症疫苗和溶瘤病毒療法
• 其他

7. 全球癌症免疫療法藥物研發外包市場（按地區分類）

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商格局（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Covance Inc
  • Explicyte
  • Aquila BioMedical
  • Horizon Discovery Group PLC
  • Crown Bioscience Inc
  • Promega Corporation
  • HD Biosciences Co. Ltd
  • BPS Bioscience Inc
  • Genscript Biotech Corporation
  • DiscoverX Corporation
  • Celentyx Ltd
  • ImmunXperts SA
  • Personalis Inc
  • STC Biologics
  • Molecular Imaging Inc

The Cancer Immunotherapy Drug Discovery Outsourcing Market size is expected to reach USD 5.62 Billion in 2034 from USD 2.30 Billion (2025) growing at a CAGR of 10.42% during 2026-2034.

The cancer immunotherapy drug discovery outsourcing market is poised for significant growth, driven by the increasing demand for innovative cancer treatments and the rising complexity of drug development processes. Immunotherapy has emerged as a promising approach to cancer treatment, harnessing the body's immune system to target and destroy cancer cells. As pharmaceutical companies seek to accelerate their drug discovery efforts and reduce costs, the outsourcing of immunotherapy research and development activities is becoming increasingly common, positioning this market for robust expansion.

Moreover, advancements in immunotherapy technologies are driving innovation within the market. The development of novel therapeutic agents, such as monoclonal antibodies, CAR-T cell therapies, and immune checkpoint inhibitors, is revolutionizing cancer treatment and creating new opportunities for outsourcing partnerships. These innovations not only enhance the efficacy of cancer therapies but also require specialized expertise and resources, making outsourcing an attractive option for many organizations. As research continues to explore new immunotherapeutic approaches and combination therapies, the cancer immunotherapy drug discovery outsourcing market is likely to expand further, driven by the promise of improved patient outcomes and accelerated drug development timelines.

Additionally, the growing emphasis on collaboration and strategic partnerships is shaping the cancer immunotherapy drug discovery outsourcing landscape. As stakeholders recognize the value of leveraging external expertise and resources, the formation of alliances between pharmaceutical companies and contract research organizations (CROs) is becoming more prevalent. These partnerships enable companies to access specialized knowledge, advanced technologies, and efficient processes that can enhance the drug discovery pipeline. As the cancer immunotherapy drug discovery outsourcing market continues to evolve, the focus on collaboration and innovation will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service Type

• Target Identification and Validation
• Lead Screening and Characterization
• Cell-based Assays

By Cancer Type

• Lung
• Breast
• Colorectal
• Melanoma
• Prostate
• Head and Neck
• Ovarian
• Pancreatic

By Drug Type

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines and Oncolytic Viral Therapy
• Others

COMPANIES PROFILED

• Covance Inc, Explicyte, Aquila BioMedical, Horizon Discovery Group PLC, Crown Bioscience Inc, Promega Corporation, HD Biosciences Co Ltd, BPS Bioscience Inc, Genscript Biotech Corporation, DiscoverX Corporation, Celentyx Ltd, ImmunXperts SA, Personalis Inc, STC Biologics, Molecular Imaging Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Service Type
• 4.2. Target Identification and Validation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lead Screening and Characterization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell-based Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Prostate Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Head and Neck Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Ovarian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Pancreatic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Type
• 6.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cancer Vaccines and Oncolytic Viral Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Service Type
  • 7.2.2 By Cancer Type
  • 7.2.3 By Drug Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Service Type
  • 7.3.2 By Cancer Type
  • 7.3.3 By Drug Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Service Type
  • 7.4.2 By Cancer Type
  • 7.4.3 By Drug Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Service Type
  • 7.5.2 By Cancer Type
  • 7.5.3 By Drug Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Service Type
  • 7.6.2 By Cancer Type
  • 7.6.3 By Drug Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Covance Inc
  • 9.2.2 Explicyte
  • 9.2.3 Aquila BioMedical
  • 9.2.4 Horizon Discovery Group PLC
  • 9.2.5 Crown Bioscience Inc
  • 9.2.6 Promega Corporation
  • 9.2.7 HD Biosciences Co. Ltd
  • 9.2.8 BPS Bioscience Inc
  • 9.2.9 Genscript Biotech Corporation
  • 9.2.10 DiscoverX Corporation
  • 9.2.11 Celentyx Ltd
  • 9.2.12 ImmunXperts SA
  • 9.2.13 Personalis Inc
  • 9.2.14 STC Biologics
  • 9.2.15 Molecular Imaging Inc